Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 695-702

  Becerra, Carlos R ^a,b   Salazar, Ramon ^c   Garcia Carbonero, Rocio ^d   Thomas, Anne L ^e   Vázquez Mazón, Federico J ^f   Cassidy, James ^g   Maughan, Tim ^h   Castillo, Manuel Gallén ⁱ   Iveson, Tim ^j   Yin, Donghua ^k   Green, Stephanie ^k   Bergsland, Emily K ^l  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b US Oncology   (United States)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f Elche University Hospital   (Spain)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ HOSPITAL DEL MAR   (Spain)

^j UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^k PFIZER INC   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Figitumumab; Metastatic colorectal cancer; Phase II; Safety

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FIGITUMUMAB; FLUOROPYRIMIDINE; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONSTIPATION; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LETHARGY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REFRACTORY METASTATIC COLORECTAL CANCER; SYSTEMIC THERAPY; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 84898056516     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2391-2     Document Type: Article

References (22)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
2. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2013) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019
3. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
4. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697-4705
5. Joulain F, Proskorovsky I, Allegra C, Tabernero J, Hoyle M, Iqbal SU, Van Cutsem E (2013) Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer 109:1735-1743
6. Shahda S, Saif MW (2013) Regorafenib: from bench to bedside in colorectal cancer. Expert Rev Clin Pharmacol 6:243-248
7. López-Calderero I, Sánchez Chávez E, García-Carbonero R (2010) The insulin-like growth factor pathway as a target for cancer therapy. Clin Transl Oncol 12:326-338
8. Donovan EA, Kummar S (2008) Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 66:91-98
9. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073
10. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS (2007) Phase I dose escalation study of the anti insulin-like growth factor-1 receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840
11. Ii M, Li H, Adachi Y, Yamamoto H, Ohashi H, Taniguchi H, Arimura Y, Carbone DP, Imai K, Shinomura Y (2011) The efficacy of IGF-1 receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras status. Clin Cancer Res 17:5048-5049
12. National Cancer Institute (2012) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed 23 March 2012
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950-3957
15. Case L, Morgan T (2003) Design of Phase II cancer trials evaluating survival probabilities. BMC Med Res Methodol 3:6
16. Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS (2011) Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 10:2331-2338
17. Yin D, Sleight B, Alvey C, Hansson AG, Bello A (2013) Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants. J Clin Pharmacol 53:21-28
18. Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534-4540
19. Retraction (2012) Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 107:2024
20. Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E, Moxhon A, Mignion L, Guigay J, Knoops L, Hamoir M, Machiels JP (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23:2153-2161
21. Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker A, Pollak M (2012) A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18:3407-3413
22. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, de Bono JS, Gualberto A, Hammer GD (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765-773